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Highlights 
- 20 specific anti-guselkumab monoclonal antibodies were generated and characterized 
- An accurate and precise ELISA to quantify guselkumab was developed 
- The guselkumab ELISA was validated in moderate-to-severe psoriasis patients 
- Two different ELISAs to detect anti-guselkumab antibodies were developed 
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Abstract  
 
Therapeutic drug monitoring, which is the measurement of drug concentrations in the 
blood, is a useful tool to guide clinical decision-making and treatment adjustments, on the 
condition that drug concentrations are correlated with treatment response. For guselkumab, 
an anti-IL-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis, such a 
concentration-response relationship could not yet be determined as no commercial assays 
for the quantification of this drug or antibodies against this drug are available. Therefore, the 
aim of this study was to develop and validate immunoassays for the quantification of 
guselkumab and anti-guselkumab antibodies according to the guidelines of the European 
Medicines Agency (EMA). A diverse panel of 20 highly specific anti-guselkumab monoclonal 
antibodies (MA-GUS) was generated of which eight revealed a neutralizing capacity of 
≥65%. At least seven different antibody clusters were identified based on their epitope 
binning profile. Using MA-GUS9F6 as the capture antibody and MA-GUS12G12 as the 
detection antibody, an ELISA was developed with a dose-response curve ranging from 0.08 
to 5 ng/mL. The assay was specific, selectivity and could accurately and precisely quantify 
guselkumab concentrations in spiked healthy control serum and serum from guselkumab-
treated psoriasis patients with a cut-off for quantification of 0.014 µg/mL. The presence of IL-
23 in physiological concentrations or of non-neutralizing antibodies did not impact the 
quantification of guselkumab, while the presence of neutralizing antibodies did. Using MA-
GUS12A9 as a calibrator, two anti-guselkumab antibody assays were developed to detect 
anti-guselkumab antibodies, which differ in the threshold for detection and quantification and 
the tolerance to the presence of guselkumab. Together, these validated immunoassays are 
essential to establish a concentration-response relationship and will allow the future 
implementation of therapeutic drug monitoring in moderate-to-severe psoriasis patients 
receiving guselkumab treatment. 
 
 
Keywords:  
Guselkumab Psoriasis Enzyme-linked immunosorbent assay Immunogenicity Therapeutic 
drug monitoring Monoclonal antibodies 
 
1. Introduction 
 
Guselkumab (Tremfya®) is a fully human IgG1λ monoclonal antibody that targets the 
p19 subunit of interleukin (IL)-23, thereby preventing the activation of T helper 17 cells and 
inhibiting the production of the pro-inflammatory cytokines IL-17 and IL-22 [1]. The pivotal 
phase III trials (VOYAGE 1 and VOYAGE 2) have demonstrated the efficacy of this biological 
in psoriasis patients resulting in the approval of guselkumab for the treatment of adult 
patients with moderate-to-severe plaque psoriasis [2-4].  
 
Despite its proven therapeutic efficacy, the treatment response to guselkumab can 
vary considerably between patients. Some patients respond favorably to therapy while others 
do not show any improvement or show an initial response but lose this response over time. 
In certain patients, this non-response could be explained by a drug concentration that is too 
low, or by the presence of anti-drug antibodies [5]. 
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Preventing loss of response to biologicals is a challenge for clinicians treating patients 
with psoriasis but strategies to aid in clinical decision-making are emerging. An important 
strategy is therapeutic drug monitoring (TDM), the measurement of drug concentrations 
which can serve as a tool to optimize biological treatment by identifying under- or 
overexposed patients and evaluating potential reasons for treatment failure [6]. Two 
fundamental requirements to perform TDM are the availability of an assay to quantify drug 
concentrations and the presence of a concentration-response relationship [7]. 
 
Several research groups have demonstrated the relationship between the serum 
concentration of adalimumab, an anti-tumor necrosis factor antibody, and clinical response in 
psoriasis patients [8, 9]. More recently, a similar relationship was observed for the anti-IL-
12/23 antibody ustekinumab and the anti-IL17A antibody secukinumab [10-12]. For 
guselkumab, no information on the presence of a concentration-response relationship or the 
value of TDM could be found in literature as there is currently no commercial assay available 
for the quantification of this drug. 
  
Therefore, the aim of this study was to develop and validate immunoassays for the 
quantification of guselkumab and anti-guselkumab antibody concentrations in serum of 
moderate-to-severe psoriasis patients, using in-house generated monoclonal antibodies. The 
assay validation was performed according to the guidelines of the European Medicines 
Agency (EMA) for bioanalytical method validation of ligand-binding assays [13]. 
2. Material and methods 
 
2.1 Materials 
Bovine serum albumin (BSA), Tween-80, citric acid, sulfuric acid (H2SO4), Ethylene 
Diamine Tetraacetic Acid (EDTA), TRIS base and hydrogen peroxide (H2O2) were purchased 
from Sigma-Aldrich. Sodium chloride, sodium carbonate and disodium hydrogen phosphate 
dihydrate (Na2HPO4 - 2H2O) were purchased from VWR International. Potassium dihydrogen 
phosphate (KH2PO4) and Sulfo-NHS-LC-Biotin were purchased from Thermo Fisher 
Scientific Inc. Potassium chloride (KCl) and o-phenylenediamine (OPD) were purchased from 
Acros Organics and streptavidin poly-HRP from Sanquin Reagents. Acetic acid was 
purchased from Chem-Lab NV. Polystyrene 96-well EIA/ RIA plates (flat bottom) were 
purchased from Corning and the CELLine bioreactor flasks from Merck. 
Guselkumab (Tremfya®) was purchased from Johnson and Johnson, secukinumab 
(Cosentyx®) from Novartis, whereas the human IgG-mixture (Multigam®) was purchased from 
C.A.F-D.C.F. IL-23 was obtained from PeproTech. Human serum from healthy donors further 
referred to as “healthy control serum”, was purchased from Valley Biomedical. 
 
The following buffers were used: PBS (140 mM NaCl, 8 mM Na2HPO4-2H2O, 2.7 mM 
KCl and 1.5 mM KH2PO4), PTAE (PBS with 0.1% BSA; 0.002% Tween-80; 5 mM EDTA), 
citrate buffer (0.1 M sodium citrate, 0.2 M disodium phosphate), block buffer (1% BSA in 
PBS) and wash buffer (PBS with 0.002% Tween-80). 
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2.2 Patients 
Serum samples of ten moderate-to-severe psoriasis patients treated with guselkumab 
were collected by the Department of Dermatology of Ghent University Hospital (Ghent, 
Belgium) in the framework of the BIOLOPTIM-GUS study (ClinicalTrials.gov Identifier: 
NCT04080648). The local ethics committee approved the study (B670201836638) and all 
patients provided written informed consent. Patients received the standard treatment 
regimen of 100 mg subcutaneously at weeks 0 and 4 followed by 100 mg every 8 weeks. 
Blood was collected in serum-separating tubes and serum was obtained by centrifugation of 
the tubes for 15 min at 1700 g at room temperature. The serum samples were divided into 
aliquots and stored at -20°C until analysis. Serum samples were prospectively collected 
before the start of treatment and at weeks 1, 2, 3, 4, 12 and 20. The Psoriasis Area and 
Severity Index (PASI) was used to assess disease activity which takes into account the 
severity and the body area that is affected. 
 
2.3 Generation and characterization of a unique panel of monoclonal 
antibodies against GUS (MA-GUS) 
2.3.1 Monoclonal antibody generation and purification 
Monoclonal antibodies against guselkumab (MA-GUS) were generated in SJL/J mice 
according to the hybridoma technology of Galfré and Milstein with approval from the ethical 
committee (172/2017 KU Leuven, Leuven, Belgium) [14]. MA-GUS were purified on a 
ProSep-vA Ultra column (Merk Millipore) as described by Van Stappen et al [15]. 
 
2.3.2 Selection of 20 hybridomas to create a diverse panel of MA-GUS 
2.3.2.1 Evaluation of the cross-reactivity of MA-GUS  
Using a sandwich-type enzyme-linked immunosorbent assay (ELISA), the cross-
reactivity towards secukinumab (an anti-IL17A antibody) and Multigam® (a human 
immunoglobulin G mixture) was determined. Briefly, guselkumab, secukinumab, and 
Multigam® were coated overnight at 4°C in a 96-well plate at a concentration of 4 µg/mL in 
PBS. After blocking for 2 h at room temperature (RT), hybridoma medium containing MA-
GUS was applied in a 1:10 and 1:100 dilution and incubated overnight at 4°C. An HRP-
conjugated rabbit anti-mouse antibody (RAM/mIg/PO; Nordic-MUbio, 1:10000 diluted) was 
used to detect bound MA-GUS. Subsequently, the color reaction was initiated using OPD 
(0.4 g/L) and H2O2 (0.003%) in citrate buffer. The reaction was stopped with H2SO4 (4 M) and 
the absorbance was measured at 492 nm. MA-GUS revealing a cross-reactivity less than 
20% towards secukinumab and Multigam® were considered as specific antibodies and 
selected for further characterization. 
 
2.3.2.2 Evaluation of the bridging capacity of MA-GUS 
The bridging capacity of each MA-GUS was evaluated by incubating the respective 
hybridoma medium (1:40 diluted) for 2 h at 21°C on a guselkumab-coated plate. Guselkumab 
was labeled with Sulfo-NHS-LC-Biotin according to the manufacturer’s instructions and 
applied on the plate in a 1:400 dilution for 1 h at 21°C to detect bound guselkumab. 
Thereafter, HRP-streptavidin was added for 30 min at 21°C and shaken at 300 rpm. The 
bridging capacity of each MA-GUS was based on the respective optical density (OD) relative 
to the OD of the MA-GUS with the highest OD. MA-GUS of which the OD was ≤5%, 6-20%, 
21-50% and >50% of the MA-GUS with the highest OD was categorized as “no bridging 
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capacity”, “low bridging capacity”, “intermediate bridging capacity” and “high bridging 
capacity”, respectively. 
 
2.3.3 Evaluation of the neutralizing capacity of MA-GUS 
Using an IL-23-based competition assay, the neutralizing capacity of the generated 
MA-GUS was determined. IL-23 was coated at 0.5 µg/mL on a 96-well plate and incubated 
overnight at 4°C. Guselkumab (4 µg/mL) was pre-incubated with MA-GUS (8 µg/mL, 1:2 
ratio) for 15 min at 37°C. After blocking for 2 h at RT and washing the plate, the GUS:MA-
GUS mix was applied on the plate followed by a 2 h incubation period at 37°C. Residual 
binding of guselkumab to IL-23 was measured by the addition of HRP-conjugated polyclonal 
goat anti-human IgG Fc (GAHu/IgG(Fc)/PO; Nordic-MUbio, 1:4000 diluted) and incubation 
for 2 h at RT. MA-GUS were considered to be neutralizing when the binding of guselkumab 
was reduced with at least 65%. 
  
2.3.4 Epitope binning of MA-GUS 
 A competitive ELISA was carried out to establish the binning profile of each MA-GUS. 
Specifically, 4 µg/mL of guselkumab was coated on a 96 well-plate for 72 h at 4°C. After 
blocking for 2 h at RT, 10 µg/mL MA-GUS (“cold-antibody”) was applied on the plate and 
incubated overnight at 4°C. Then, plates were washed and a biotin-labeled conjugate of each 
MA-GUS was applied at a final concentration of at least 25 ng/mL followed by incubation for 
2 h at RT. After washing, binding of biotin-labeled MA-GUS was determined using 
streptavidin poly-HRP. The OD obtained for each biotin-labeled MA-GUS in the absence and 
in the presence of the “cold antibody” was compared. MA-GUS of which the 
𝑂𝐷+𝑐𝑜𝑙𝑑 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
𝑂𝐷−𝑐𝑜𝑙𝑑 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
 
gave a percentage lower than 20%, were considered as competitive with the cold antibody. 
Principal component analysis (PCA) and clustering were performed using the online web tool 
ClustVis (https://biit.cs.ut.ee/clustvis/) to group the 20 MA-GUS according to similar binding 
sites towards guselkumab. 
2.4 Development and validation of the guselkumab ELISA 
2.4.1 Development of the guselkumab ELISA  
 MA-GUS was coated at 4 µg/mL overnight at 4°C followed by blocking with PBS 
containing 1% BSA. Samples were diluted 1:100 to 1:800 in PTAE buffer for concentrations 
<0.5 µg/mL, 1:400 to 1:3200 for concentrations between 0.5 µg/mL and 5 µg/mL and 1:1600 
to 1:12800 for concentrations >5 µg/mL. Thereafter, the samples were applied on the plate 
and shaken at 300 rpm for 2 h at 21°C. Biotinylated MA-GUS was added and incubated for 1 
h at 21°C to detect bound guselkumab. After washing, HRP-streptavidin was applied and 
incubated for 30 min at 21°C. Subsequently, the plate was developed using OPD (0.4 g/L) 
and H2O2 (0.003%) in citrate buffer and the reaction was stopped with H2SO4 (4 M). The 
absorbance was measured at 492 nm and the guselkumab dose-response curve was 
analyzed by non-linear regression using Graphpad Prism 8.2.1 (Graph Software, San Diego, 
CA, USA).  
 
2.4.2 Specificity 
The specificity of the guselkumab assay was determined by spiking secukinumab (10; 
20 and 30 µg/mL) and guselkumab (0.10 and 5.00 µg/mL) to guselkumab-naive serum 
samples of psoriasis patients. Thereafter, the guselkumab concentration was determined. 
The assay is defined as specific when the recovery of guselkumab is 75-125% [13]. 
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Additionally, five serum samples of secukinumab-treated psoriasis patients were measured 
with the guselkumab assay.  
 
2.4.3 Selectivity 
2.4.3.1 Impact of the matrix on guselkumab determination 
The impact of unrelated compounds in the matrix, i.e. serum of psoriasis patients, on 
the determination of guselkumab was evaluated by spiking guselkumab (0.10 and 5.00 
µg/mL) to 10 guselkumab-naive psoriasis serum samples. Thereafter, the guselkumab 
concentration was determined. The assay is defined as selective when the recovery of 
guselkumab is 80-120% in at least 80% of the evaluated samples [13]. 
 
2.4.3.2 Impact of IL-23 on guselkumab determination 
 To evaluate the potential interference of IL-23 on the determination of guselkumab, 
varying concentrations of IL-23 (0.1-2.5 µg/mL, molecular weight = 53.5 kDa) were spiked to 
1 µg/mL guselkumab (molecular weight = 146.61 kDa) in PTAE buffer. The IL-23-GUS 
mixture was pre-incubated for 15 min at 37°C on a shaker (300 rpm) and applied in a 1:400 
dilution on a MA-GUS coated plate for the detection of guselkumab. Subsequently, the 
residual binding of guselkumab was determined. 
 
2.4.3.3 Impact of anti-guselkumab antibodies on guselkumab determination 
The impact of anti-guselkumab antibodies on the determination of guselkumab was 
assessed by the addition of a two-fold excess (2 µg/mL) of MA-GUS to guselkumab (1 
µg/mL) in PTAE buffer. For this experiment, 5 MA-GUS with varying neutralizing capacities 
were selected. After incubation for 15 min at 37°C and 300 rpm, the mixture was diluted 
1:400 and applied on the plate. Subsequently, the residual binding of guselkumab was 
determined. 
2.4.4 Determination of the assay cut-off values for detection and quantification, 
accuracy, imprecision and dilutional linearity 
The assay lower limit of detection (LLOD), the lower limit of quantification (LLOQ), 
and cut-off values for detection and quantification were determined using a panel of 15 
guselkumab-naive serum samples of psoriasis patients. The LLOD and LLOQ were 
calculated based on the mean OD of 15 guselkumab-naive serum samples plus 3 times and 
10 times the standard deviation, respectively. The cut-off values for detection and 
quantification were set based on the calculated LLOD and LLOQ multiplied by the assay 
dilution factor. 
  
The intra- and inter-assay accuracy and precision were determined by preparing 5 
quality control samples (0.10; 0.25; 0.50; 2.00 and 5.00 µg/mL guselkumab) in healthy 
control serum and measuring four sets within one run for the intra-assay evaluation and six 
times one set, each on a different day, for the inter-assay evaluation. Acceptable criteria for 
accuracy and imprecision were defined as a recovery of 80-120% (75-125% for LLOQ) and a 
coefficient of variation (CV) of ≤20% (≤25% for LLOQ). Furthermore, the total error (i.e. the 
sum of the absolute value of the % relative error and % CV) should not exceed 30% (40% at 
LLOQ)[13]. 
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To evaluate dilutional linearity, two quality control samples (2.00 µg/mL and 5.00 
µg/mL guselkumab) were prepared in healthy control serum and applied on the plate in a 
dilution of 1:400 to 1:3200 and 1:1600 to 1:12800, respectively. Acceptable criteria for 
accuracy and imprecision were defined as a recovery of 80-120% and a CV of ≤20%. 
Moreover, the precision between the measured values in a dilution series should not exceed 
30% [13]. 
 
2.4.5 Validation of the guselkumab ELISA in a cohort of moderate-to-severe psoriasis 
patients 
Serum samples of 10 moderate-to-severe psoriasis patients under standard 
guselkumab treatment were measured with the guselkumab ELISA. The accuracy of incurred 
samples was evaluated by reanalysis of the samples in separate runs at different days with a 
total of four repeats. The concentration obtained for the initial analysis and the concentration 
obtained by reanalysis should be within 30% of their mean for at least 67% of the repeats. 
Moreover, the precision between the measured values in a dilution series should not exceed 
30% [13]. 
 
2.5 Development and validation of the anti-guselkumab antibody ELISAs 
2.5.1 Development of the anti-guselkumab antibody bridging ELISA 
Guselkumab was coated at 0.5 µg/mL overnight at 4°C followed by blocking with PBS 
containing 1% BSA for 2 h at RT. Samples were diluted 1:20 to 1:160 in PTAE buffer, applied 
on the plate and incubated for 2 h at 21°C on a plate shaker (300 rpm). After washing, 
biotinylated guselkumab (diluted 1:4000) was added and shaken for 1 h at 21°C for the 
detection of bound MA-GUS. Afterward, HRP-streptavidin was applied and incubated for 30 
min at 21°C. Plates were washed and developed using OPD (0.4 g/L) and H2O2 (0.003%) in 
citrate buffer and the reaction was stopped with H2SO4 (4 M). The absorbance was measured 
at 492 nm and the guselkumab dose-response curve was analyzed by non-linear regression 
using Graphpad Prism 8.2.1 (Graph Software, San Diego, CA, USA). 
 
2.5.2 Development of the anti-guselkumab antibody ACE ELISA 
An affinity capture elution (ACE) assay was developed that allows the detection of 
anti-guselkumab antibodies in the presence of drug. In this assay, guselkumab/anti-
guselkumab antibody complexes were dissociated by acidification with acetic acid (pH 3, 300 
mM) for 10-15 min at RT. The acidified samples were immediately applied on a plate coated 
with 5 µg/mL guselkumab that contained 25 µl of TRIS buffer (pH 9.5, 1 M) to neutralize the 
samples. After incubation at RT for 1 h, plates were washed and a second acidification step 
was performed to dissociate the anti-guselkumab antibodies from the coated drug. Next, the 
supernatant was transferred into a new plate containing TRIS buffer (pH 9.5, 1 M) and 
incubated for 1 h at RT to allow the anti-guselkumab antibodies present in the supernatant to 
bind to the plate. Taken all acidification and neutralization steps into account, the final 
dilution of the sample is 1:17.78. After blocking and washing the plate, anti-guselkumab 
antibodies bound to the plate were detected by the addition of biotinylated guselkumab for 1 
h at RT. Finally, HRP-streptavidin was applied and incubated for 30 min at 21°C. Plates were 
washed and developed using OPD (0.4 g/L) and H2O2 (0.003%) in citrate buffer and the 
reaction was stopped with H2SO4 (4 M). The absorbance was measured at 492 nm and the 
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guselkumab dose-response curve was analyzed by non-linear regression using Graphpad 
Prism 8.2.1 (Graph Software, San Diego, CA, USA). 
 
2.5.3 Specificity 
The specificity of the anti-guselkumab antibody bridging and ACE assay was 
determined by spiking secukinumab (10; 20 and 30 µg/mL) and MA-GUS12A9 (50 and 200 
ng/mL for the bridging assay and 2250 and 9000 ng/mL for the ACE assay) to guselkumab-
naive serum samples of psoriasis patients. Thereafter, the anti-guselkumab antibody 
concentration was determined. The assay is defined as specific when the recovery of anti-
guselkumab antibodies is 75-125% [13]. 
 
2.5.4 Selectivity 
The impact of unrelated compounds in the matrix, i.e. serum of psoriasis patients, on 
the determination of anti-guselkumab antibodies in the bridging and ACE assay was 
evaluated by spiking MA-GUS12A9 (50 ng/mL for the bridging assay and 2250 ng/mL for the 
ACE assay) to 10 guselkumab-naive psoriasis serum samples. Thereafter, the anti-
guselkumab antibody concentration was determined. The assay is defined as selective when 
the recovery of anti-guselkumab antibodies is 80-120% in at least 80% of the evaluated 
samples [13]. 
 
2.5.5 Determination of the assay cut-off values for detection and quantification, 
accuracy and imprecision  
The assay LLOD, LLOQ and cut-off values for detection and quantification for the 
anti-guselkumab antibody bridging and ACE assay were determined using a panel of 25 
guselkumab-naive serum samples of psoriasis patients as described in paragraph 2.4.4. 
  
The intra- and inter-assay accuracy and imprecision were determined by preparing 3 
quality control samples (50; 100 and 200 ng/mL MA-GUS12A9 for the bridging assay and 
2250; 4500 and 9000 ng/mL MA-GUS12A9 for the ACE assay) in healthy control serum and 
measuring six sets within one run for the intra-assay evaluation and four times one set, each 
on a different day, for the inter-assay evaluation. Acceptable criteria for accuracy and 
imprecision were defined as a recovery of 80-120% (75-125% for LLOQ) and a coefficient of 
variation (CV) of ≤20% (≤25% for LLOQ). Furthermore, the total error (i.e. the sum of the 
absolute value of the % relative error and % CV) should not exceed 30% (40% at LLOQ) 
[13]. 
 
2.5.6 Evaluation of the drug tolerance 
The interference of guselkumab with the determination of anti-guselkumab antibodies, 
i.e. the drug tolerance, was assessed by incubating increasing concentrations of guselkumab 
(1-8 µg/mL) to 4 µg/mL MA-GUS12A9, the antibody selected as calibrator. After 15 min 
incubation of the GUS:MA-GUS complex at 37°C, residual binding of MA-GUS12A9 was 
measured in both the bridging assay and the ACE assay. The percentage recovery of MA-
GUS12A9 in the presence of guselkumab was expressed relative to the percentage recovery 
of MA-GUS12A9 in the absence of guselkumab, which was set at 100%. 
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3. Results 
 
3.1 Characterization of a unique panel of monoclonal antibodies against 
guselkumab (MA-GUS) 
3.1.1 Selection of 20 hybridomas to create a diverse panel of MA-GUS 
 A total of 144 hybridomas producing monoclonal antibodies that bind to guselkumab 
were generated. The cross-reactivity was evaluated by counter-screening for binding to 
secukinumab (an anti-IL17A antibody) and Multigam(a human IgG mixture) resulting in a 
total of 73 hybridomas binding exclusively to guselkumab (Figure 1). To facilitate further 
antibody selection for assay development, the growth rate of the hybridoma and the ability of 
the antibody to cross-link coated guselkumab with biotin-labeled guselkumab, i.e. the 
bridging capacity, was evaluated. Of the 49 viable hybridomas, 28 had no bridging capacity, 
8 had a low bridging capacity, 7 an intermediate bridging capacity and 6 a high bridging 
capacity. Of each group, several hybridomas were selected in order to create a diverse panel 
of 20 different guselkumab-specific antibodies that can be used for further assay 
development.  
 
3.1.2 Neutralizing capacity of guselkumab-specific MA-GUS 
The neutralizing capacity of the 20 MA-GUS was determined using an IL-23-based 
competition assay. Eight MA-GUS reduced the binding signal of guselkumab to IL-23 with ≥ 
65% when using at 2-fold excess of antibody over guselkumab and were considered 
neutralizing. One antibody had no neutralizing capacity (<10%), while the 11 remaining 
antibodies had an intermediate neutralizing capacity (ranging from 37 to 62%). 
 
3.1.3 Epitope binning of guselkumab specific MA-GUS 
The results of the epitope binning experiment were visualized using principal 
component analysis (PCA). The score plot shows the first two principal components (PC), 
PC1 on the X-axis and PC2 on the Y-axis, explaining 76.3% and 9.7% of the total variance, 
respectively (Fig. 2). The 20 MA-GUS were clustered in seven different groups, each group 
containing antibodies that are directed towards a similar guselkumab binding site. 
 
3.2 Development and validation of the guselkumab ELISA  
3.2.1 Development of the guselkumab ELISA 
The 20 selected MA-GUS were pairwise tested for their suitability as capture and 
detection antibody in the development of an ELISA to quantify the concentration of 
guselkumab. Based on the affinity, the absence of serum interference and the interdilution, 
MA-GUS9F6 was selected as the capture antibody and MA-GUS12G12 as the detection 
antibody. MA-GUS9F6 and MA-GUS12G12 had a neutralizing capacity of 72% and 58%, 
respectively and bind to different epitopes of guselkumab (clusters 1 and 6). Using this 
combination, a non-linear guselkumab calibration dose-response curve, that ranged from 
0.08 to 5 ng/mL was obtained (Suppl. Fig. 1).  
 
3.2.2 Specificity 
The specificity of the guselkumab assay was determined by spiking secukinumab, a 
human anti-IL-17A monoclonal antibody frequently used in the treatment of psoriasis, and 
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guselkumab to drug-naive serum samples of psoriasis patients. In these samples, 
guselkumab could accurately be measured (recovery of 95-111%), demonstrating the 
specificity of the assay. Moreover, in five serum samples of secukinumab-treated 
guselkumab-naive psoriasis patients (with secukinumab concentrations ranging from 13.1-
49.0 µg/mL) guselkumab was undetectable. 
 
3.2.3 Selectivity 
The selectivity of the guselkumab assay was determined by evaluating the impact of 
the matrix (serum of psoriasis patients), the target (IL-23) and anti-guselkumab antibodies on 
the measurement of guselkumab.  
 
3.2.3.1 Impact of the matrix on guselkumab determination 
Guselkumab was spiked to guselkumab-naive serum samples of psoriasis patients to 
evaluate the impact of unrelated compounds in the matrix on guselkumab determination. The 
matrix did not affect the quantification of guselkumab concentrations as the accuracy of 95% 
of the spiked samples was within the acceptable range (recoveries ranging from 81-117%). 
 
3.2.3.2 Impact of IL-23 on guselkumab determination 
Varying concentrations of IL-23 were spiked to 1 µg/mL guselkumab to determine the 
impact of IL-23 on guselkumab determination. The assay could quantify guselkumab 
(recovery of 80%) in the presence of up to 1 µg/mL IL-23 (= 2.74:1 molar ratio of IL-23 versus 
guselkumab, Fig. 3A). Once exceeding this IL-23 concentration, guselkumab could still be 
detected but not accurately quantified (recovery below 80%). Nevertheless, even in the 
presence of 2.5 µg/mL IL-23 (= 6.85:1 molar ratio of IL-23 versus guselkumab), the detection 
of guselkumab was not completely blocked. 
 
3.2.3.3 Impact of anti-guselkumab antibodies on guselkumab determination 
The influence of a two-fold excess of five MA-GUS with varying neutralizing capacities 
on the determination of 1 µg/mL guselkumab was evaluated. In the control samples with only 
guselkumab or with the addition of a non-relevant anti-ixekizumab antibody (MA-IXE66F11), 
the concentration of guselkumab was accurately detected (Fig. 3B). The addition of the non-
neutralizing antibody (MA-GUS14D11, neutralizing capacity = 5%) did not significantly impair 
the quantification of guselkumab (recovery of 84%). In contrast, the addition of intermediate 
neutralizing antibodies (MA-GUS6G1, neutralizing capacity = 40% and MA-GUS18A4 
neutralizing capacity = 38%) revealed less than 25% recovery of guselkumab, while the 
addition of neutralizing antibodies (MA-GUS12A9 and MA-GUS13A10, neutralizing capacity 
more than 65%) completely hampered guselkumab detection. 
 
3.2.4 Assay cut-off values for detection and quantification, accuracy and imprecision 
The cut-off values for detection and quantification were determined based on the OD 
of 15 guselkumab-naive serum samples of psoriasis patients. The mean OD was 0.061 with 
a standard deviation of 0.012, resulting in a LLOD of 0.073 ng/mL and LLOQ of 0.137 ng/mL. 
Taking into account the dilution factor of 1:100, the cut-off value for guselkumab detection 
and quantification was 0.007 µg/mL and 0.014 µg/mL, respectively. 
 
The assay complied with the requirements for intra-assay accuracy and precision with 
recoveries ranging from 81% to 101% and CV of ≤12% and inter-assay accuracy and 
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precision with recoveries ranging from 89% to 107% and CV of ≤13% for all quality control 
samples tested. Furthermore, the total error did not exceed 17% and 25%, for the inter-assay 
and intra-assay evaluation, respectively. 
 
3.2.5 Minimum required dilution and dilutional linearity 
The minimum required dilution was determined to be 1:100. For samples with a 
guselkumab concentration between 0.5 µg/mL and 5 µg/mL, a dilution of 1:400 to 1:3200 
was applied and concentrations >5 µg/mL were diluted 1:1600 to 1:12800. Quality control 
samples of 2 and 5 µg/mL guselkumab could accurately (recovery of 89% and 94%, 
respectively) and precisely (CV of 3% and 4%, respectively) be quantified showing that 
concentrations exceeding the range of quantification can be reliably measured by the 
guselkumab assay after proper dilution. Moreover, the precision between the measured 
values in a dilution series of each quality control sample was acceptable (CV <30%). 
 
3.2.6 Validation of the guselkumab ELISA in a cohort of moderate-to-severe psoriasis 
patients 
The ability of the newly developed assay to measure guselkumab concentrations in 
patient’s serum was determined by the application of the guselkumab ELISA on serum 
samples of 10 moderate-to-severe psoriasis patients under standard guselkumab treatment 
(Figure 4). The guselkumab concentrations that were measured ranged from 0.46 to 10.36 
µg/mL. Guselkumab could be detected during induction at weeks (w) 1, 2, 3 and 4 after the 
start of guselkumab treatment (w1, 2, 3: intermediate time points and w4: trough, i.e. the time 
point right before the next administration) and at weeks 12 and 20 (trough). 
 
To evaluate accuracy of incurred samples, all patient samples were measured four 
times. For each sample, at least 67% of the repeats lied within 30% of its mean. Moreover, 
the precision between the measured values in a dilution series of all patient samples was 
acceptable (CV <30%) demonstrating parallelism between the calibration standard curve and 
serially diluted patient samples and excluding a possible matrix effect. 
 
3.3 Development and validation of the anti-guselkumab antibody ELISAs 
3.3.1 Development of the anti-guselkumab antibody assays 
Two assays to measure anti-guselkumab antibodies were developed: an anti-
guselkumab antibody bridging assay and an anti-guselkumab antibody ACE assay. 
 
The suitability of different MA-GUS as calibrator antibody in the anti-guselkumab 
antibody bridging ELISA was evaluated. Based on the ability to cross-link plate-coated 
guselkumab with biotinylated guselkumab and the obtained dose-response curve, MA-
GUS12A9 was selected as calibrator antibody for anti-guselkumab antibody quantification. 
Using GUS12A9 as a calibrator, a non-linear dose-response curve was obtained in the range 
of 0.16-10 ng/mL (Suppl. Fig. 2, panel A).  
Additionally, an anti-guselkumab antibody ACE assay was developed that allows the 
detection of anti-guselkumab antibodies in the presence of drug. The same calibrator as in 
the bridging assay, GUS12A9, was used and yielded a non-linear dose-response curve 
ranging from 0.98 to 1000 ng/mL (Suppl. Fig. 2, panel B). 
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3.3.2 Specificity  
The specificity of the anti-guselkumab antibody assays was determined by spiking 
secukinumab, a human anti-IL-17A monoclonal antibody frequently used in the treatment of 
psoriasis, and MA-GUS12A9 to drug-naive serum samples of psoriasis patients. In both the 
bridging and ACE assay, anti-guselkumab antibodies could accurately be measured, as the 
recovery of MA-GUS12A9 was 110-124% and 82-118%, respectively, demonstrating the 
specificity of the assays. 
 
3.3.3 Selectivity  
MA-GUS12A9 was spiked to guselkumab-naive serum samples of psoriasis patients 
to evaluate the impact of unrelated compounds in the matrix on anti-guselkumab antibody 
determination. In the bridging assay, the matrix in a dilution of 1/20 did not affect the 
quantification of anti-guselkumab antibodies as the accuracy of 90% of the spiked samples 
was within the acceptable range with recoveries ranging from 90-120%. In the ACE assay, 
the recovery of anti-guselkumab antibodies in spiked psoriasis serum was within 88-107% in 
80% of the samples. 
 
3.3.4 Assay cut-off values for detection and quantification, accuracy and imprecision 
The cut-off values for detection and quantification of anti-guselkumab antibodies in 
the bridging and ACE assay were determined based on the OD of 25 guselkumab-naive 
serum samples of psoriasis patients. In the bridging assay, the mean OD was 0.06 with a 
standard deviation of 0.01, resulting in a LLOD of 0.186 ng/mL and LLOQ of 0.348 ng/mL. 
Taking into account the dilution factor of 1:20, the cut-off value for guselkumab detection and 
quantification was 3.7 ng/mL and 7.0 ng/mL MA-GUS12A9 equivalents, respectively. In the 
ACE assay, the mean OD was 0.075 with a standard deviation of 0.012, resulting in a LLOD 
of 25.56 ng/mL and LLOQ of 50.38 ng/mL. Taking into account the dilution factor of 1:17.78, 
the cut-off value for guselkumab detection and quantification were set at 454 ng/mL and 896 
ng/mL MA-GUS12A9 equivalents, respectively. 
 
The bridging assay complied with the requirements for intra-assay accuracy and 
precision with recoveries ranging from 81% to 119% (and CV of ≤12%) and inter-assay 
accuracy and precision with recoveries ranging from 101% to 103% (and CV of ≤17%) for all 
quality control samples tested. A similar conclusion can be drawn for the ACE assay as the 
intra-assay accuracy and precision was shown to be 83% to 118% (and CV of ≤19%) and the 
inter-assay accuracy and precision was 91% to 113% (and CV of ≤14%) for all quality control 
samples tested. 
 
3.3.5 Evaluation of the drug tolerance 
To evaluate the impact of guselkumab on the detection of anti-guselkumab 
antibodies, i.e. the drug tolerance, increasing concentrations of guselkumab were spiked to 4 
µg/mL MA-GUS12A9 resulting in GUS:MA-GUS ratios ranging from 0.25:1 to 2:1. The 
addition of guselkumab reduced the detection of MA-GUS12A9 in a concentration-dependent 
manner (Fig. 5). The presence of 1 µg/mL guselkumab (= ratio 0.25:1) already decreased the 
recovery of MA-GUS12A9 to below 80% in both the bridging assay and the ACE assay. In 
the anti-guselkumab antibody bridging assay, MA-GUS12A9 became undetectable in the 
presence of 3 µg/mL guselkumab (= ratio 0.75:1), while an average recovery of 29% was 
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observed in the ACE assay with the same guselkumab concentration. Interestingly, in 
contrast to the bridging assay, MA-GUS12A9 remains detectable in the presence of up to 8 
µg/mL guselkumab in the ACE assay, although in low concentrations. 
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4. Discussion 
 
TDM of biologicals is an emerging tool to optimize treatment as drug concentrations 
have been linked to clinical outcomes in various chronic inflammatory diseases [9-11, 16-19]. 
Multiple studies indicate that monitoring drug concentrations together with a clinical 
evaluation, will not only maximize treatment outcomes but will also improve the cost-
effectiveness of biological therapies [20, 21]. To date, TDM of guselkumab in patients with 
moderate-to-severe psoriasis cannot be performed in daily clinical practice because no 
commercial assays to measure guselkumab or anti-guselkumab antibody concentrations are 
available. In this study, we aimed to develop immunoassays for the quantification of 
guselkumab and anti-guselkumab antibody concentrations according to the guidelines of 
EMA. 
 
A diverse panel of 20 highly specific anti-guselkumab monoclonal antibodies was 
generated and characterized for their neutralizing capacity and epitope binning profile. This 
allowed to carefully select the best antibody combination for the development of an assay to 
measure guselkumab. Using MA-GUS9F6 as the capture antibody and MA-GUS12G12 as 
the detection antibody, an ELISA was developed which accurately and precisely quantified 
guselkumab concentrations with a cut-off for quantification of 0.014 µg/mL. The mean (±SD) 
steady-state trough serum guselkumab concentrations in two phase III studies were reported 
to be 1.15±0.73µg/mL and 1.23±0.84 µg/mL [5]. As TDM is most often performed at trough, 
our in-house developed guselkumab assay can quantify guselkumab in a clinically relevant 
concentration range with a good sensitivity.  
 
The guselkumab assay was shown to be selective as no matrix effect of serum of 
psoriasis patients was observed. Moreover, the presence of the drug’s target, IL-23, did not 
influence the quantification of guselkumab until a concentration of 0.25 µg/mL, indicating that 
the presence of IL-23 at physiological concentrations (pg/mL) will not have an impact on the 
quantification of guselkumab [22]. In contrast, the presence of neutralizing anti-guselkumab 
monoclonal antibodies, but not non-neutralizing ones, severely hampered the detection of 
guselkumab. This can be explained by the fact that the coating antibody MA-GUS9F6 is also 
a neutralizing antibody and other neutralizing antibodies consequently compete for a similar 
binding site. Hampering of drug detection by neutralizing anti-drug antibodies has also been 
observed with other ELISAs that quantify biologicals [15, 23]. 
 
With the aim to perform a clinical validation, serum samples of 10 moderate-to-severe 
psoriasis patients collected at several time points during standard guselkumab treatment 
were applied on the guselkumab assay. The high sensitivity of the assay allowed to measure 
guselkumab concentrations during the induction and maintenance phase, both at 
intermediate time points (weeks 1, 2 and 3 after the start of treatment) and at trough (weeks 
4, 12 and 20), indicating that this assay can be used to perform TDM in guselkumab-treated 
psoriasis patients. Moreover, the guselkumab concentrations observed at week 20 were 
comparable to the data reported in clinical trials [5]. Currently, clinical studies evaluating the 
efficacy and safety of guselkumab in the treatment of inflammatory bowel disease and 
psoriatic arthritis are ongoing [24-26]. If guselkumab is approved for these indications, the 
developed assays will also be very useful to evaluate the value of monitoring guselkumab 
and anti-guselkumab antibodies in these other chronic inflammatory diseases. 
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Anti-drug antibodies can have a significant impact on treatment response. Multiple 
studies have shown that anti-infliximab and anti-adalimumab antibodies are associated with 
lower serum drug concentrations and loss of response in psoriasis patients [27-29]. The 
clinical relevance of anti-guselkumab antibodies is not well established because of the lack of 
appropriate assays. Therefore, two assays were developed to detect anti-guselkumab 
antibodies, i.e. a bridging assay and an ACE assay. The specificity and selectivity of both 
anti-guselkumab antibody assays was demonstrated. 
Both anti-guselkumab antibody assays use the same calibrator, MA-GUS12A9, to 
detect anti-guselkumab antibodies but differ in the threshold for anti-guselkumab antibody 
detection and quantification and the tolerance to the presence of guselkumab. In the bridging 
assay, the cut-off value for detection and quantification was determined to be 3.7 ng/mL and 
7 ng/mL respectively. In contrast, the cut-off values of the ACE assay are 454 ng/mL and 896 
ng/mL for detection and quantification, respectively. These are considerably higher 
compared to the bridging assay, which can be explained by the fact that due to the different 
acidification steps, the sample is automatically diluted to a certain extent. On the other hand, 
the acid dissociation steps allow the detection of anti-drug antibodies that were previously in 
complex with the drug. As a result, the ACE assay can still detect antibodies in the presence 
of up to 8 µg/mL guselkumab, whereas the bridging assay cannot detect anti-guselkumab 
antibodies from a guselkumab concentration of 3 µg/mL onwards. These assays will allow to 
further elucidate the clinical relevance of anti-guselkumab-antibodies, either free or in 
complex with the drug. 
 
Together, the guselkumab and anti-guselkumab antibody assays will allow to 
evaluate the presence of a concentration-response relationship and establish a therapeutic 
window in patients receiving guselkumab treatment and may support the use of TDM in 
guselkumab-treated patients. 
5. Conclusion 
 
In conclusion, 20 highly specific anti-guselkumab monoclonal antibodies were 
generated, characterized and pairwise tested for the development of an ELISA for the 
quantification of guselkumab concentrations in serum of patients with moderate-to-severe 
psoriasis. Additionally, an anti-guselkumab antibody bridging and ACE assay were 
developed for the detection of anti-guselkumab antibodies, either free or in complex with 
guselkumab. All three assays were validated according to the EMA guidelines. These 
validated immunoassays are essential to establish a concentration-response relationship and 
will allow the future implementation of TDM in moderate-to-severe psoriasis patients 
receiving guselkumab. 
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Figure captions 
 
Figure 1: Flowchart of the selection of 20 guselkumab-specific MA-GUS 
 
Figure 2: Principal component analysis and clustering of the 20 MA-GUS 
 
Figure 3: Effect of IL-23 (panel A) and different antibodies (panel B) on the determination of 
guselkumab (1 µg/mL) in the ELISA using MA-GUS9F6 as the capture antibody and MA-
GUS12G12 as the detection antibody (mean ± SD). Both graphs are representative of 2 
independent experiments with 2 replicates each. 
 
Figure 4: The average guselkumab serum concentration (mean ± SD) of 10 moderate-to-
severe psoriasis patients at different time points after the start of guselkumab treatment. The 
patients received 100 mg guselkumab subcutaneously at weeks 0, 4, 12 and 20 according to 
the standard dosing regimen. The graph shows the results of 2 independent experiments 
with 2 replicates each. 
 
Figure 5: The drug tolerance of the anti-guselkumab antibody bridging assay (black dots) 
and anti-guselkumab antibody ACE assay (white dots) was evaluated by incubating 
increasing concentrations of guselkumab with 4 µg/mL MA-GUS12A9. The percentage 
recovery of MA-GUS12A9 in the presence of guselkumab was expressed relative to the 
percentage recovery of MA-GUS12A9 in the absence of guselkumab, which was set at 
100%. The graph shows the results of 2 independent experiments with 2 replicates each. 
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